| Patient | Ella Fitzgerald |
|---|---|
| Date of birth | 1956-04-25 |
| Identifiers | MRN HR-ML029-SYN; SSN (made up) 000-29-3640 |
| Document date | 2026-05-11 |
| Author | Odessa Whitlow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Claudication of both calves, worse on the right, in a 70-year-old touring singer with type 2 diabetes, coronary bypass surgery last year, and an ankle-brachial index of 0.62 right and 0.74 left. Please define the arterial disease, advise on exercise and antithrombotic therapy, and tell us whether and when revascularization should be considered, so that her limbs are protected before any tissue is lost. [S]
Urgency: Within two to three weeks, on the same day as her two-week primary care visit. [S]
Questions for the consultant:
Calf cramping after about one and a half blocks for about a year, now limiting her walks through airports and to the stage; no rest pain, wounds, or color change. Diabetes for many years with retinopathy; A1c 8.6% with low glucose readings after late shows, so glipizide was stopped today, glargine reduced to 24 units and moved to the morning, and empagliflozin started. Five-vessel coronary bypass surgery last year; no angina; on aspirin 81 mg, metoprolol succinate 25 mg, and atorvastatin, raised today from 40 to 80 mg for an LDL of 92 mg/dL. Never smoked. Examination: femoral pulses present; popliteal and foot pulses absent on the right and foot pulses faint on the left; calluses under the second metatarsal heads and hammer toes; protective sensation intact; no ulcer (IWGDF risk category 2). Ankle-brachial index 0.62 right and 0.74 left; toe-brachial index 0.46 and 0.55. Creatinine 0.92 mg/dL, eGFR 67, potassium 4.4 mmol/L; urine albumin-creatinine ratio 18 mg/g; hemoglobin 12.4 g/dL. Right macular edema; retina clinic appointment pending. She tours in the United States and overseas and wants to keep performing; she decides who is told about her health [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
6 later historical claims are omitted because they describe events after the index age. See the teaching note.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with breakfast and the evening meal | Oral route | 2016-03-01 | active | S |
| Glipizide 10 mg oral tablet, one tablet by mouth twice daily before meals | One tablet by mouth twice daily before breakfast and the evening meal | Oral route | 2021-09-01 to 2026-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime | 30 units at bedtime | Subcutaneous route | 2023-04-01 to 2026-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 24 units under the skin each morning | 24 units each morning, at the same clock time on tour, with written time-zone adjustments | Subcutaneous route | 2026-05-11 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-06-02 to 2026-05-11 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-11 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-06-02 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-06-02 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgery | Oral route | 2026-05-11 | active | S |
| Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose | One spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911 | Nasal route | 2026-05-11 | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complications | active | confirmed | E11.51 | S — Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic. |
| Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problems | active | confirmed | E11.3311 | S — Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display. |
| Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgery | active | confirmed | I25.10 | S — Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display. |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1970s | Diabetes affecting her eyes, with health problems beginning in the 1970s | D (CLM-0007) |
| 1970s | Cataract surgery, after which she returned to touring more than 40 weeks a year | D (CLM-0008) |
| 1986 | Intensive care admission for heart trouble and quintuple-bypass heart surgery | D (CLM-0009) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died suddenly of a heart attack in 1932; age at death not recorded in the cited source | D (CLM-0002) |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-11 | Body height | 165 | cm | S |
| 2026-05-11 | Body weight | 84 | kg | S |
| 2026-05-11 | Body mass index (BMI) [Ratio] | 30.9 | kg/m2 | S |
| 2026-05-11 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-05-11 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-05-11 | Heart rate | 62 | /min | S |
| 2026-05-11 | Respiratory rate | 16 | /min | S |
| 2026-05-11 | Body temperature | 36.6 | Cel | S |
| 2026-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-11 | Hemoglobin A1c/Hemoglobin.total in Blood | 8.6 | % | Below 5.7% is normal; her individualized goal is below 7.5% | High | S |
| 2026-05-11 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-11 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 67 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-11 | Glucose [Mass/volume] in Serum or Plasma | 168 | mg/dL | 70-99 mg/dL | High | S |
| 2026-05-11 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | <=30 mg/g | Normal | S |
| 2026-05-11 | Cholesterol [Mass/volume] in Serum or Plasma | 164 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-05-11 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 92 | mg/dL | Her goal with coronary and peripheral artery disease is below 55 mg/dL | Normal | S |
| 2026-05-11 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 | mg/dL | >=50 mg/dL | Low | S |
| 2026-05-11 | Triglyceride [Mass/volume] in Serum or Plasma | 140 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-05-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 2026-05-11 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 10-35 U/L | Normal | S |
| 2026-05-11 | Hemoglobin [Mass/volume] in Blood | 12.4 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-05-11 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 386 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-05-11 | Ankle-brachial index | 0.62 | {ratio} | 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal | Low | S |
| 2026-05-11 | Ankle-brachial index | 0.74 | {ratio} | 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal | Low | S |
| 2026-05-11 | Toe brachial index - right | 0.46 | {ratio} | Above 0.70 normal | Low | S |
| 2026-05-11 | Toe brachial index - left | 0.55 | {ratio} | Above 0.70 normal | Low | S |
| 2026-05-11 | Visual acuity best corrected Right eye by ETDRS eye chart | 64 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Low | S |
| 2026-05-11 | Visual acuity best corrected Left eye by ETDRS eye chart | 81 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Normal | S |